Suzhou, China – March 26, 2026
CStone Pharmaceuticals announced significant clinical progress for its trispecific antibody CS2009, highlighting strong Phase I/II data demonstrating excellent safety, high response rates, and broad antitumor activity across multiple cancer types. The innovative therapy, targeting PD-1, VEGF, and CTLA-4 pathways, represents a next-generation approach in immuno-oncology drug development, with plans to advance into global Phase III trials by the end of 2026.
Strong Safety Profile and Favorable Tolerability
Clinical data from ongoing global Phase I/II studies show that CS2009 has demonstrated an excellent safety profile in heavily pretreated patients with advanced solid tumors, addressing a major limitation seen in traditional combination immunotherapies. Among 113 patients enrolled in Phase I, the therapy showed no dose-limiting toxicities and no maximum tolerated dose reached, indicating strong tolerability across multiple dose levels.
Importantly, the incidence of Grade ≥3 treatment-related adverse events was limited to 23%, while severe immune-related adverse events remained relatively low. Unlike conventional regimens combining CTLA-4 and PD-1 inhibitors, CS2009 did not demonstrate excessive toxicity, suggesting a more balanced and patient-friendly safety profile. This safety advantage is critical for enabling long-term treatment and broader clinical use, particularly in patients with advanced-stage cancers.
High Efficacy Signals Across Multiple Tumor Types
Advertisement
CS2009 has shown compelling efficacy across multiple tumor indications, including both common and difficult-to-treat cancers, reinforcing its potential as a broad-spectrum immunotherapy. In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression, the therapy achieved a remarkable objective response rate (ORR) of 90% and a disease control rate (DCR) of 100%, indicating strong clinical benefit.
In later-line NSCLC patients, CS2009 maintained efficacy with an ORR of 25%, while also demonstrating activity in traditionally resistant “cold tumors.” Notably, the therapy achieved an ORR of 40% in non-clear cell renal cell carcinoma (nccRCC) and 33.3% in soft tissue sarcoma (STS), highlighting its ability to generate responses in tumor types that are typically less responsive to immunotherapy.
Additionally, Phase II studies evaluating CS2009 in combination with chemotherapy have shown promising efficacy and favorable tolerability, without increasing chemotherapy-related toxicity. These findings underscore the therapy’s potential for combination strategies in first-line treatment settings, further expanding its clinical applicability.
Advancing Toward Global Phase III Development
Building on these encouraging results, CStone plans to initiate global multi-regional Phase III clinical trials (MRCTs) by the end of 2026, targeting key indications such as NSCLC, colorectal cancer (CRC), and small cell lung cancer (SCLC). This strategic advancement reflects confidence in CS2009’s potential to become a first- or best-in-class therapy in the competitive oncology landscape.
Further clinical data are expected to be presented at major international conferences, including the American Society of Clinical Oncology (ASCO) Annual Meeting and the European Society for Medical Oncology (ESMO) Congress, which will provide deeper insights into the therapy’s long-term efficacy and safety profile.
CS2009’s unique mechanism of action combines immune checkpoint inhibition and anti-angiogenic effects, enabling multidimensional tumor targeting. By simultaneously activating T cells, reversing immune suppression, and improving the tumor microenvironment, the therapy represents a next-generation innovation in cancer immunotherapy.
Overall, the latest clinical data position CS2009 as a highly promising oncology candidate with strong safety, robust efficacy, and broad therapeutic potential, supporting its advancement into late-stage development. As the global oncology market continues to evolve toward precision medicine and multi-target therapies, CS2009 could play a key role in shaping the future of cancer treatment and improving outcomes for patients with advanced malignancies.
Source: CStone Pharmaceuticals press release
